A Phase 2 interventional study of Topical ceftazidime and vancomycin in Thoracolumbar Spinal Fusion, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Utah · Phase 2, Interventional, and Prevention
Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.
Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 122nd largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 32 of the 33 other live ones, and was the 202nd registered.
745 studies on the registry are indexed under Surgical Wound Infection; 151 are open to participants now.
Browse Surgical Wound Infection studies →31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Macro Biologics, Inc. · Sites in United States
Ages 18+
Riverside University Health System Medical Center · Sites in United States
Ages 18+ · Women only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Rhode Island Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Surgical Wound Infection studies recruiting now, 60 (71%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 15 · Phase 3 33 · Phase 4 39
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 200 across 581 interventional studies indexed under Surgical Wound Infection.
Median enrollment 208 across the 177 interventional studies, 300 across the 23 observational. Of the 144 that completed or were terminated, 78 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 202 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 996 studies on the registry; 177 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
12 of the studies in Surgical Wound Infection with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06014411Hospital for Special Surgery, New YorkEarly Versus Delayed Bathing of Orthopaedic Surgical Wounds | 2026-12 |
| NCT04773457Boston Children's HospitalNeutrophil Phenotypic Profiling and Surgical Site Infections in Surgical Patients | 2026-12-01 |
| NCT04725916Sean DevittStudying How Outpatient Water affEcts Risks With Drains (SHOWER Study) | 2026-12-15 |
| NCT06378359University of MinnesotaEffectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients | 2026-12-31 |
| NCT07379684Macro Biologics, Inc.A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 202 studies in Surgical Wound Infection with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research team hypothesizes that ceftazidime, in conjunction with vancomycin, is a safe and effective way to prevent surgical site infections in lumbar spinal surgery.
Objective 1: Evaluate the drain and serum concentrations of ceftazidime + vancomycin from 0-3 days postoperative. Hypothesis: The investigators hypothesize that intrawound ceftazidime will remain concentrated at the wound site, and there will be minimal absorption of ceftazidime into the circulatory system.
Objective 2: Evaluate incidence of surgical site infections (within 90 days postoperative) and pseudoarthrosis (within 2 years postoperative) after the use of ceftazidime in addition to vancomycin. Hypothesis: The investigators hypothesize that intrawound ceftazidime, in conjunction with intrawound vancomycin, is a safe and effective way to reduce surgical site infections following lumbar spine surgery, while having little effect on construct fusion (e.g., pseudoarthrosis).
Objective 3: Evaluate ceftazidime concentration effects on osteoblasts, specifically metabolic activity and osteogenic protein expression profiles. Hypothesis: The investigators hypothesize that ceftazidime concentrations measured from drain samples will not have an effect on metabolic activity and osteogenic protein expression of osteoblasts.
Surgical site infections (SSI) present a challenge in orthopedic spine surgery and can cause significant morbidity and mortality, as well as increased healthcare costs. Reported incidence of spine SSI varies from 1-14%, with primary lumbar fusions at 8.8% and revision lumbar fusions at 12.2%. Current practices to prevent SSIs include the use of topical antibiotics, particularly vancomycin, in addition to standard intra-operational IV antibiotics.
However, previous studies show conflicting evidence regarding the efficacy of topical vancomycin in the prevention of SSIs. As such, there is no clear guidance on the use of topical antibiotics in the prevention of SSIs, and the US FDA has not approved local application of vancomycin for this purpose.
In addition, there are several adverse effects that may result from the use of local vancomycin. With frequent vancomycin use, causal organisms of SSIs are shifting towards gram negative pathogens rather than MSSA and MRSA, which have historically been the predominant cause of SSIs in orthopedics. Local use of vancomycin also increases the risk of nonunion and pseudarthrosis, as vancomycin inhibits the migration potential of osteoblasts, which may result in the interference of bone remodeling.
With no clear recommendation of the use of local vancomycin, as well as the trend towards gram-negative pathogens, there is a need to investigate the efficacy of other topical antibiotics for the prevention of SSIs. Ceftazidime is a broad-spectrum third generation cephalosporin, with mainly gram-negative coverage. This study aims to evaluate the safety and efficacy of ceftazidime, in conjunction with vancomycin, in post-operative prophylaxis of SSI following lumbar spine instrumentation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical ceftazidime and vancomycin after lumbar spinal fusion surgery
Drug: Topical ceftazidime and vancomycin
1g:1g ratio of topical ceftazidime and vancomycin after lumbar spinal fusion surgery.
Also known as: Ceftazidime - Fortaz, Tazicef, Ceptaz, Zacicefta, Vancomycin - Vancocin, Firvanq, Tyzavan
Infections
Incidence of surgical site infections
Time frame: 90 days postoperative
Started Jul 2026 (actual). Primary completion is estimated for Jul 2030, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.